Ticker
GILD

Price
63.59
Stock movement down
-0.03 (-0.05%)
Company name
Gilead Sciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
79.76B
Ent value
118.63B
Price/Sales
2.90
Price/Book
-
Div yield
4.59%
Div growth
9.07%
Growth years
6
FCF payout
26.35%
Trailing P/E
17.67
Forward P/E
10.01
PEG
12.62
EPS growth
-10.50%
1 year return
-10.95%
3 year return
0.31%
5 year return
-2.92%
10 year return
8.45%
Last updated: 2022-08-25

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.92
Dividend yield4.59%
Payout frequencyQuarterly
Maximum yield5.06%
Average yield3.83%
Minimum yield2.43%
Discount to avg yield16.50%
Upside potential19.75%
Yield as % of max yield90.77%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield4.59%
Current yield distribution11.35%
Yield at 100% (Min)2.43%
Yield at 90%2.92%
Yield at 80%3.17%
Yield at 50% (Median)3.93%
Yield at 20%4.35%
Yield at 10%4.65%
Yield at 0% (Max)5.06%

Dividend per share

Loading...
Dividend per share data
Years of growth6 years
CCC statusDividend Challenger
Dividend per share2.92
Payout frequencyQuarterly
Ex-div date14 Sep 2022
EPS (TTM)3.58
EPS (1y forward)6.35
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
GILDS&P500
DGR MR2.82%15.44%
DGR TTM3.20%7.80%
DGR 3 years7.60%3.88%
DGR 5 years9.07%4.73%
DGR 10 years-8.30%
DGR 15 years-5.82%
Time since last change announced237 days
EPS growth (5y)-10.50%
EPS growth (5y forward)1.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM59.53%26.35%
Average--
Forward45.98%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E17.67
Price to OCF7.51
Price to FCF7.82
Price to EBITDA9.55
EV to EBITDA14.20

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.90
Price to Book-
EV to Sales4.32

FINANCIALS

Per share

Loading...
Per share data
Current share count1.25B
EPS (TTM)3.58
FCF per share (TTM)8.08

Income statement

Loading...
Income statement data
Revenue (TTM)27.47B
Gross profit (TTM)20.81B
Operating income (TTM)7.22B
Net income (TTM)4.51B
EPS (TTM)3.58
EPS (1y forward)6.35

Margins

Loading...
Margins data
Gross margin (TTM)75.74%
Operating margin (TTM)26.30%
Profit margin (TTM)16.43%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash4.30B
Net receivables3.79B
Total current assets12.63B
Goodwill8.31B
Intangible assets30.33B
Property, plant and equipment0.00
Total assets63.08B
Accounts payable583.00M
Short/Current long term debt26.21B
Total current liabilities8.56B
Total liabilities43.16B
Shareholder's equity0.00
Net tangible assets-18.72B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)10.61B
Capital expenditures (TTM)414.00M
Free cash flow (TTM)10.20B
Dividends paid (TTM)2.69B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets7.16%
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open63.85
Daily high63.93
Daily low63.18
Daily Volume3.69M
All-time high122.21
1y analyst estimate69.40
Beta0.39
EPS (TTM)3.58
Dividend per share2.92
Ex-div date14 Sep 2022
Next earnings date26 Oct 2022

Downside potential

Loading...
Downside potential data
GILDS&P500
Current price drop from All-time high-47.97%-12.18%
Highest price drop-70.83%-56.47%
Date of highest drop7 Jun 19949 Mar 2009
Avg drop from high-24.87%-11.38%
Avg time to new high24 days12 days
Max time to new high1808 days1805 days
COMPANY DETAILS
GILD (Gilead Sciences Inc) company logo
Marketcap
79.76B
Marketcap category
Large-cap
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Employees
14400
Investor relations
SEC filings
CEO
Daniel O'Day
Country
USA
City
Foster City
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can...
September 24, 2022
NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International B...
September 23, 2022
Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like ot...
September 23, 2022
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
September 22, 2022
FOSTER CITY, Calif., September 22, 2022--Gilead Sciences, Inc. today announced a new public-private initiative with the Partnership for Health Advancement in Vietnam (HAIVN), a collaboration between B...
September 22, 2022
Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.
September 21, 2022
In this article, we discuss 10 defensive stocks that quant billionaire Jim Simons loves. If you want to read about some more stocks in the Simons portfolio, go directly to Quant Billionaire Jim Simons...
September 21, 2022
FOSTER CITY, Calif., September 20, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based bio...
September 20, 2022
If you want to know who really controls Gilead Sciences, Inc. ( NASDAQ:GILD ), then you'll have to look at the makeup...
September 20, 2022
Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.
September 19, 2022
Next page